Table 2.
Multivariate analyses of HDGF and VEGF
| Variable | DSS | MFS | LRFS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Category | RR | 95% CI | p-value | RR | 95% CI | p-value | RR | 95% CI | p-value | |
| Primary tumor (T) | T1-T2 | 1 | – | 0.0001* | 1 | – | 0.0003* | |||
| T3 | 1.11 | 0.40–3.12 | 1.09 | 0.41–2.88 | ||||||
| T4 | 5.98 | 2.50–14.33 | 4.39 | 2.00–9.63 | ||||||
| Histological grade | W-D | 1 | – | 0.0014* | 1 | – | 0.0009* | 1 | – | 0.0981 |
| M-D | 3.09 | 1.11–8.62 | 3.15 | 1.20–8.23 | 1.247 | 0.62–2.48 | ||||
| P-D | 7.50 | 2.48–22.67 | 6.70 | 2.50–19.60 | 2.109 | 1.04–4.27 | ||||
| Nodal status (N) | N0 | 1 | – | 0.1073 | 1 | – | 0.2104 | |||
| N1 | 2.31 | 0.90–5.95 | 1.77 | 0.76–4.10 | ||||||
| N2 | 2.98 | 1.03–8.58 | 2.37 | 0.88–6.37 | ||||||
| Post-OP CCRT | Yes | 1 | – | < 0.0001* | 1 | – | < 0.0001* | 1 | – | 0.0117* |
| No | 6.89 | 2.90–16.41 | 5.61 | 2.54–12.39 | 2.003 | 1.17–3.44 | ||||
| VEGF | Low expression | 1 | – | 0.0183* | 1 | – | 0.0153* | 1 | – | 0.0461* |
| High expression | 4.09 | 1.27–13.15 | 4.01 | 1.30–12.30 | 2.100 | 1.01–3.45 | ||||
| HDGF-N | Low expression | 1 | – | 0.0280* | 1 | – | 0.0534 | 1 | – | 0.0285* |
| High expression | 3.04 | 1.13–8.22 | 2.36 | 0.99–5.62 | 2.141 | 1.08–4.23 | ||||
Post-OP CCRT, postoperative concurrent chemoradiotherapy; W-D, well differentiated; M-D, moderately differentiated; P-D, poorly differentiated; HDGF-N, nuclear expression of hepatoma-derived growth factor; VEGF, vascular endothelial growth factor; DSS, disease-specific survival; MFS, metastasis-free survival; LRFS, local recurrence-free survival; *, Statistical significance